Allogeneic bone marrow transplantation

Southern Medical Journal

Volumn 89, Issue 9, 1996, Pages 857-868

  Tabbara, Imad A ^a,b  

^a School of Medicine ^*

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAPSONE; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; IMMUNOSUPPRESSIVE AGENT; MESNA; METHOTREXATE; METHYLPREDNISOLONE; PENTAMIDINE; PENTOXIFYLLINE; PREDNISONE; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID;

ACUTE KIDNEY FAILURE; ALLOGENIC BONE MARROW TRANSPLANTATION; ALOPECIA; ARTICLE; CARDIOMYOPATHY; CLINICAL TRIAL; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HLA MATCHING; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LIVER VENOOCCLUSIVE DISEASE; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; VIRUS INFECTION; VOMITING;

EID: 0029837060     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199609000-00003     Document Type: Article

References (113)

1. Bodmer WF, Albert E, Bodmer JG, et al.: Nomenclature for factors of the HLA system, 1987. Histocompatibility Testing 1987. Dupont B (ed). New York, Springer-Verlag, Vol 1, 1991, pp 72-79
2. Sullivan KA, Amos DB: The HLA system and its detection. Manual of Clinical Laboratory Immunology. Rose NR, Friedman H, Fahey JL (eds). Washington, DC, American Society for Microbiology, 3rd Ed, 1986, pp 835-846
3. Hansen JA, Mickelson EM, Beatty PG, et al.: Clinical bone marrow transplantation: donor selection and recipient monitoring. Manual of Clinical Laboratory Immunology. Rose NR, Friedman H, Fahey JL (eds). Washington, DC, American Society for Microbiology, 3rd Ed, 1986, pp 892-901
4. Thomsen M, Alvarez C, Carpenter CB: Analysis of HLA recombinant families by Southern blots. Histocompatibility Testing 1987. Dupont B (ed). New York, Springer-Verlag, Vol 1, 1989, pp 900-908
5. Petersdorf EW, Smith AG, Mickelson EM, et al.: The HLA-DR4f alleles defined by sequence polymorphisms within the DRB1 first domain. Immunogenetics 1991; 33:267-275
6. Lanchbury JSS, Jaeger EEM, Welsh KJ, et al.: Nucleotide sequence of a novel HLA-DR 4B1 allele, DRB1*0409. Immunogenetics 1991; 33:210-212
7. Beatty PG, Dahlberg S, Mickelson EM, et al.: Probability of finding HLA-matched unrelated marrow donors. Transplantation 1988; 45:714-718
8. Kernan NA, Bartsch G, Ash RC, et al.: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328:593-602
9. Marks DI, Cullis JO, Ward KN, et al.: Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first 2 years. Ann Intern Med 1993; 119:207-214
10. Gluckman E, Socie G, Devergie A, et al.: Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: lone-term follow-up. Blood 1991; 78:2451-2455
11. Champlin RE, Ho WG, Nimer SD, et al.: Bone marrow transplantation for severe aplastic anemia: effect of a preparative regimen of cyclophosphamide-low-dose-total lymphoid irradiation and post-transplant cyclosporine-methotrexate therapy. Transplantation 1990; 49:720-724
12. Champlin RE, Horowitz MM, van Bekkum DW, et al.: Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989; 73:606-613
13. Storb R, Etzioni R, Anasetti C, et al.: Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84:941-949
14. Clift RA, Buckner CD, Thomas ED, et al.: Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84:2036-2043
15. Storb R, Santos GW: Indications for bone marrow transplantation. DATELINE: Issues in Transplantation 1992; 3:1-20
16. Lum LG: Immune recovery after bone marrow transplantation. Hematol Oncol Clin North Am 1990; 4:659-675
17. Goodman JL, Winston DJ, Greenfield RA, et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-851
18. Shepp DH, Meyers JD: Viral infections in the compromised host. Current Therapy in Hematology-Oncology, 1985-1986. Brian MC, Carbone P (eds). Philadelphia, BC Decker, 1985, pp 102-108
19. Zaia J: Viral infections with bone marrow transplantation. Hematol Oncol Clin North Am 1990; 4:603-623
20. Saral R, Burns WH, Laskin OL, et al.: Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981; 305:63-67
21. Bowden RA, Slichter SJ, Sayers MH, et al.: Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1981; 78:246-250
22. Winston DJ, Ho WG, Lin C-H, et al.: Intravenous immunoglobulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987; 106:12-18
23. Bowden RA, Sayers M, Flournoy N, et al.: Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314:1006-1010
24. Goodrich JM, Bowden RA, Fisher L, et al.: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118:173-178
25. Winston DJ, Ho WG, Bartoni K, et al.: Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118:179-184
26. Schmidt GM, Horak DA, Niland JC, et al.: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991; 324:1005-1011
27. Weiner RS, Bortin MM, Gale RP, et al.: Interstitial pneumonitis after bone marrow transplantation. Ann Intern Med 1986; 104:168-175
28. Wingard JR, Mellits ED, Sostrin MB, et al.: Interstitial pneumonitis after allogeneic bone marrow transplantation, nine-year experience at a single institution. Medicine 1988; 67:175-186
29. Reusser P, Gambertoglio JG, Lilleby K, et al.: Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992; 166:473-479
30. Bearman SI: The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85:3005-3020
31. McDonald GB, Hinds MS, Fisher LD, et al.: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118:255-267
32. Tabbara I, Ghazal H: Early drop in protein C and antithrombin III levels is a predictor for the development of venoocclusive disease in patients undergoing bone marrow transplantation (Abstract). Blood 1994; 84:335
33. Carreras E, Granena A, Navasa M, et al.: Transjugular liver biopsy in bone marrow transplantation. Bone Marrow Transplant 1993; 11:21-26
34. Shulman HM, McDonald GB: Utility of transvenous liver biopsy and hepatic venous pressure measurements in Seattle marrow transplant recipients (Abstract). Exp Hematol 1990; 18:699
35. Bearman SI, Anderson GL, Mori M, et al.: Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11:1729-1736
36. Boglin TP, Harper P, Marcus RE: Venoocclusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplant 1990; 5:439-441
37. Bearman SI, Shuhart MC, Hinds MS, et al.: Recombinant human tissue plasminogen activator for the treatment of established severe hepatic venoocclusive disease of the liver after bone marrow transplantation. Blood 1992; 80:2458-2462
38. Bianco JA, Appelbaum FR, Nemunaitis J, et al.: Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78:1205-1211
39. Kalhs P, Lechner K, Stockshlader M, et al.: Pentoxifylline did not prevent transplant-related toxicity in 31 consecutive allogeneic bone marrow transplant recipients (Letter). Blood 1992; 80:2683-2684
40. Clift RA, Bianco JA, Appelbaum FR, et al.: A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993; 82:2025-2030
41. Attal M, Huguet F, Rubine H, et al.: Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79:1-7
42. Essell JH, Thompson JM, Harman GS, et al.: Pilot trial of prophylactic ursodiol to decrease the incidence of venoocclusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1992; 10:367-372
43. Ferrara JM, Deeg HJ: Graft-versus-host disease. N Engl J Med 1991; 324:667-671
44. Billingham RE: The biology of graft-versus-host reactions. Harvey Led 1966; 62:21
45. Glazier A, Tutschka PJ, Farmer ER, et al.: Graft-versus-host disease in cyclosporine treated rats following syngeneic and autologous bone marrow reconstitution. J Exp Med 1989; 158:1-8
46. Hess AD, Jones RJ, Morris LE, et al.: Autologous graft-versus-host diease: a new frontier in immunotherapy. Bone Marrow Transplant 1992; 10:16-21
47. Antin JH, Ferrara JLM: Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80:2964-2968
48. Antin JH: Inhibition of dysregulated cytokines to control acute graft-versus-host disease. Hem/Onc Annals 1994; 2:341-346
49. Anasetti C, Hansen JA, Waldman TA, et al.: Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994; 84:1320-1327
50. Antin JH, Weinstein HJ, Guinan EC, et al.: Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84:1342-1348
51. Gale RP, Bortin M, van Bekkum D, et al.: Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67:397-399
52. Nash RA, Pepe MS, Storb R, et al.: Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80:1838-1845
53. Storb R, Deeg HJ, Pepe M, et al.: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73:1729-1734
54. Chao NJ, Schmidt GM, Niland JC, et al.: Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329:1225-1230
55. Sullivan KM, Kopecky JK, Jocam J, et al.: Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323:705-712
56. Storb R, Prentice RL, Buckner CD, et al.: Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: beneficial effect of a protective environment. N Engl J Med 1983; 308:302-307
57. Antin J, Bierer B, Smith B, et al.: Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in hematologic malignancies. Blood 1991; 78:2139-2149
58. Martin PJ, Schoch G, Fisher L, et al.: A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76:1464-1472
59. Martin PJ, Schoch G, Fisher L, et al.: A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77:1821-1828
60. Byers VS, Henslee JP, Kernan NA, et al.: Use of anti-pan T-lymphocyte ricin A chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood 1990; 75:1426-1432
61. Weiden PL, Flournoy N, Thomas ED: Anti-leukemic effects of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1982; 306:392-396
62. Horowitz MM, Gale RP, Sondel PM, et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555-559
63. Jones RJ, Ambinder RF, Piantadosi S, et al.: Evidence of graft versus lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77:649-653
64. Smith CJ, Aarli JA, Biberfeld P, et al.: Myasthenia gravis after bone-marrow transplantation: evidence for a donor origin. N Engl J Med 1983; 309:1565-1568
65. Sullivan KM, Witherspoon RP, Storb R, et al.: Prednisone and azathioprine compared with prednisone alone and placebo for the treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72:546-554
66. Holland HK, Wingard JR, Beschorner WE, et al.: Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-versus-host disease and low serum IgG. Blood 1988; 72:621-627
67. Parker PM, Chao N, Nademanee A, et al.: Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86:3604-3609
68. Wingard JR, Piantadosi S, Vogelsang GB, et al.: Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 74:1428-1435
69. Atkinson K, Horowitz MM, Gale RP, et al.: Risk factors for chronic graft-versus-host-disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75:2459-2464
70. Weiden PL, Sullivan R, Flournoy N, et al.: Anti-leukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304:1429-1432
71. Nemunaitis J, Singer JW, Epstein C, et al.: The use of RHGM-CSF for graft failure in patients after autologous or allogeneic bone marrow transplantation (BMT) (Abstract). Exp Hematol 1989; 17:657
72. Serafino L, Arcese W, Papa G, et al.: Thyroid and pituitary function following allogenic bone marrow transplantation. Arch Intern Med 1988; 148:1066-1071
73. Mulligan SP, Joshua DE, Joasoo A, et al.: Autoimmune hyperthyroidism associated with chronic graft-versus-host disease. Transplantation 1987; 44:463-464
74. Sanders JE: Implications of cancer therapy to the head and neck on growth and development and other delayed effects. Consensus Development Conference on Oral Complications of Cancer Therapies: Diagnosis, Prevention, and Treatment. Fox PC, Janson CC (eds). Bethesda, Md, Public Health Service, NIH, 1990, NCI Monographs No 9, pp 163-167
75. Sanders JE, Seattle Marrow Transplant Team: The impact of marrow transplant preparative regimens on subsequent growth and development. Semin Hematol 1991; 28:244-249
76. Sanders JE: Impact of marrow transplantation on subsequent fertility. Hematologic Disorders in Maternal-Fetal Medicine. Bern M, Frigoletto F (eds). New York, Wiley-Liss Inc, 1990, pp 327-334
77. Deeg HJ, Flournoy N, Sullivan KM, et al.: Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation. Int J Radiat Oncol Biol Phys 1984; 10:957-964
78. Clark JG, Crawford SW, Madtes DK, et al.: Obstructive lung disease after allogeneic marrow transplantation, clinical presentation and course. Ann Intern Med 1989; 111:368-376
79. Witherspoon RP, Fisher LD, Schoch G, et al.: Secondary cancers after bone marrow transplantation for leukemia and aplastic anemia. N Engl J Med 1989; 321:784-789
80. Zutter MM, Martin PJ, Sale GE, et al.: Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72:520-529
81. Socie G, Kolb HJ, Ljungman P, et al.: Malignant diseases after allogeneic bone marrow transplantation: the case for assessment of risk factors. Br J Haematol 1992; 80:427-430
82. Santos GW, Tutschka PJ, Brookmeyer R, et al.: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309:1347-1353
83. Clift RA, Buckner CD, Appelbaum FR, et al.: Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992; 10:1723-1729
84. Barrett AJ, Horowitz MM, Ash RC, et al.: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992; 79:3067-3070
85. Chao NJ, Forman SJ, Schmidt GM, et al.: Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood 1991; 78:1923-1927
86. Goldman JM, McGlave P, Szydlo P, et al.: Impact of disease duration and prior treatment on outcome of bone marrow transplants for chronic myelogenous leukemia (CML) (Abstract). Blood 1992; 80(suppl 1):170a
87. Biggs JC, Szer J, Grilley P, et al.: Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy 2. Blood 1992; 80:1352-1357
88. Hehlman R, Heimpel H, Hasford J, et al.: Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 1993; 82:398-407
89. Anderson JE, Appelbaum FR, Fisher LD, et al.: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82:677-681
90. Gahrton G, Tura S, Ljungman P, et al.: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13:1312-1322
91. Chopra R, Goldstone AH, Pearce R, et al.: Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10:1690-1695
92. Ratanatharathorn V, Uberti J, Karanes C, et al.: Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84:1050-1055
93. Lucarelli G, Galimberti M, Polchi P, et al.: Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322:417-421
94. Vermylen C, Fernandez Robles E, Nivane J, et al.: Bone marrow transplantation in five children with sickle cell anaemia. Lancet 1988; 1:1427-1428
95. Giralt SA, Champlin RE: Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 1994; 84:3603-3612
96. Giralt S, Escudier S, Kantarjian H, et al.: Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 1993; 329:757-761
97. Wagner JE, Vogelsang GB, Zehnbauer BA, et al.: Relapse of leukemia after bone marrow transplantation: effect of second myeloblative therapy. Bone Marrow Transplant 1992; 9:205-209
98. Radich JP, Sanders JE, Buckner CD, et al.: Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11:304-311
99. Nemunaitis J, Rabinowe SN, Singer JW, et al.: Recombinant granulocyte-macrophage colony factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324:1773-1779
100. Gorin N, Coiffier B, Hayat M, et al.: Recombinant human granulocyte-macrophage colony-stimulating factor after high dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double blind placebo controlled trial. Blood 1992; 80:1149-1155
101. Taylor K, Jagannath S, Spitzer G, et al.: Recombinant human granulocyle-colony stimulating factor hastens granulocyte recovery after high dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 1989; 7:1791-1798
102. Schriber JR, Negrin RS, Chao NJ, et al.: The efficacy of granulocyte colony stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged marrow. Leukemia 1993; 7:1491-1497
103. Nemunaitis J, Buckner CD, Appelbaum FR, et al.: Phase I/II trial of recombinant granulocyte-macrophage colony stimulating factor following allogeneic bone marrow transplantation. Blood 1991; 77:2065-2068
104. Powles R, Smith C, Milan S, et al.: Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukemia: double blind placebo controlled trial. Lancet 1990; 336:1417-1423
105. DeWitte T, Gratwohl A, Van Der LN, et al.: Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 1992; 79:1359-1364
106. Nemunaitis J, Rosenfeld C, Ash R, et al.: Phase III double blind trial of rh GM-CSF following allogeneic bone marrow transplantation (Abstract). Blood 1993; 82:1128a
107. Anasetti C, Anderson G, Appelbaum FR, et al.: Phase III study of rh GM-CSF in allogeneic marrow transplantation from unrelated donors (Abstract). Blood 1993; 82:1799a
108. Masaoka T, Takaku F, Kato S, et al.: Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation. Exp Hematol 1989; 17:1047-1052
109. Linch D, Scarffe H, Proctor S, et al.: Randomized vehicle controlled dose finding study of glycosylated recombinant human granulocyte colony stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1993; 11:307-312
110. Schriber JR, Chao NJ, Long GD, et al.: Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994; 84:1680-1684
111. Bensinger WI, Weaver CH, Appelbaum FR, et al.: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85:1655-1658
112. Korbling M, Przepiorka D, Huh YO, et al.: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85:1659-1665
113. Schmitz N, Dreger P, Suttorp M, et al.: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85:1666-1672